Literature DB >> 29185901

Identification of Distant Metastatic Disease in Uterine Cervical and Endometrial Cancers with FDG PET/CT: Analysis from the ACRIN 6671/GOG 0233 Multicenter Trial.

Michael S Gee1, Mostafa Atri1, Andriy I Bandos1, Robert S Mannel1, Michael A Gold1, Susanna I Lee1.   

Abstract

Purpose To assess the accuracy of staging positron emission tomography (PET)/computed tomography (CT) in detecting distant metastasis in patients with local-regionally advanced cervical and high-risk endometrial cancer in the clinical trial by the American College of Radiology Imaging Network (ACRIN) and the Gynecology Oncology Group (GOG) (ACRIN 6671/GOG 0233) and to compare central and institutional reader performance. Materials and Methods In this prospective multicenter trial, PET/CT and clinical data were reviewed for patients enrolled in ACRIN 6671/GOG 0233. Two central readers, blinded to site read and reference standard, reviewed PET/CT images for distant metastasis. Central review was then compared with institutional point-of-care interpretation. Reference standard was pathologic and imaging follow-up. Test performance for central and site reviews of PET/CT images was calculated and receiver operating characteristic analysis was performed. Generalized estimating equations and nonparametric bootstrap procedure for clustered data were used to assess statistical significance. Results There were 153 patients with cervical cancer and 203 patients with endometrial cancer enrolled at 28 sites. Overall prevalence of distant metastasis was 13.7% (21 of 153) for cervical cancer and 11.8% (24 of 203) for endometrial cancer. Central reader PET/CT interpretation demonstrated sensitivity, specificity, positive predictive value (PPV), and negative predictive value of 54.8%, 97.7%, 79.3%, and 93.1% for cervical cancer metastasis versus 64.6%, 98.6%, 86.1%, and 95.4% for endometrial cancer, respectively. By comparison, local institutional review demonstrated sensitivity, specificity, PPV, and negative predictive value of 47.6%, 93.9%, 55.6%, and 91.9% for cervical cancer metastasis and 66.7%, 93.9%, 59.3%, and 95.5% for endometrial cancer, respectively. For central readers, the specificity and PPV of PET/CT detection of cervical and endometrial cancer metastases were all significantly higher compared with that of local institutional review (P < .05). Central reader area under the receiver operating characteristic curve (AUC) values were 0.78 and 0.89 for cervical and endometrial cancer, respectively; these were not significantly different from local institutional AUC values (0.75 and 0.84, respectively; P > .05 for both). Conclusion FDG PET/CT demonstrates high specificity and PPV for detecting distant metastasis in cervical and endometrial cancer and should be included in the staging evaluation. Blinded central review of imaging provides improved specificity and PPV for the detection of metastases and should be considered for future oncologic imaging clinical trials. © RSNA, 2017.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29185901      PMCID: PMC5881639          DOI: 10.1148/radiol.2017170963

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  15 in total

Review 1.  Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?

Authors:  Lori E Dodd; Edward L Korn; Boris Freidlin; C Carl Jaffe; Lawrence V Rubinstein; Janet Dancey; Margaret M Mooney
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

Review 2.  Diagnostic performance of fluorine 18 fluorodeoxyglucose positron emission tomography imaging for detection of primary lesion and staging of endometrial cancer patients: systematic review and meta-analysis of the literature.

Authors:  Vahid Reza Dabbagh Kakhki; Sara Shahriari; Giorgio Treglia; Malihe Hasanzadeh; Seyed Rasoul Zakavi; Zohreh Yousefi; Sima Kadkhodayan; Ramin Sadeghi
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

Review 3.  Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.

Authors:  Christine M Bestvina; Gini F Fleming
Journal:  Oncologist       Date:  2016-07-13

4.  Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial.

Authors:  Mostafa Atri; Zheng Zhang; Farrokh Dehdashti; Susanna I Lee; Shamshad Ali; Helga Marques; Wui-Jin Koh; Kathleen Moore; Lisa Landrum; Jae Weon Kim; Paul DiSilvestro; Eric Eisenhauer; Frederick Schnell; Michael Gold
Journal:  Gynecol Oncol       Date:  2016-07-27       Impact factor: 5.482

5.  Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial.

Authors:  Mostafa Atri; Zheng Zhang; Farrokh Dehdashti; Susanna I Lee; Helga Marques; Shamshad Ali; Wui-Jin Koh; Robert S Mannel; Paul DiSilvestro; Stephanie A King; Michael Pearl; XunClare Zhou; Marie Plante; Katherine M Moxley; Michael Gold
Journal:  Radiology       Date:  2017-01-03       Impact factor: 11.105

6.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

7.  Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.

Authors:  J Tate Thigpen; Mark F Brady; Howard D Homesley; John Malfetano; Brent DuBeshter; Robert A Burger; Shu Liao
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

8.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

Authors:  Pierluigi Benedetti Panici; Stefano Basile; Francesco Maneschi; Andrea Alberto Lissoni; Mauro Signorelli; Giovanni Scambia; Roberto Angioli; Saverio Tateo; Giorgia Mangili; Dionyssios Katsaros; Gaetano Garozzo; Elio Campagnutta; Nicoletta Donadello; Stefano Greggi; Mauro Melpignano; Francesco Raspagliesi; Nicola Ragni; Gennaro Cormio; Roberto Grassi; Massimo Franchi; Diana Giannarelli; Roldano Fossati; Valter Torri; Mariangela Amoroso; Clara Crocè; Costantino Mangioni
Journal:  J Natl Cancer Inst       Date:  2008-11-25       Impact factor: 13.506

9.  Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.

Authors:  Erik Mittra; Tarek El-Maghraby; Cesar A Rodriguez; Andrew Quon; I Ross McDougall; Sanjiv S Gambhir; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

Review 10.  Advances in diagnosis and treatment of metastatic cervical cancer.

Authors:  Haoran Li; Xiaohua Wu; Xi Cheng
Journal:  J Gynecol Oncol       Date:  2016-07       Impact factor: 4.401

View more
  18 in total

1.  Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study.

Authors:  Katherine I Stewart; Beth Chasen; William Erwin; Nicole Fleming; Shannon N Westin; Shayan Dioun; Michael Frumovitz; Pedro T Ramirez; Karen H Lu; Franklin Wong; Thomas A Aloia; Pamela T Soliman
Journal:  Cancer       Date:  2019-06-21       Impact factor: 6.860

2.  Detection of distant metastatic disease by positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) at initial staging of cervical carcinoma.

Authors:  Alexander Lin; Sirui Ma; Farrokh Dehdashti; Stephanie Markovina; Julie Schwarz; Barry Siegel; Matthew Powell; Perry Grigsby
Journal:  Int J Gynecol Cancer       Date:  2019-02-09       Impact factor: 3.437

3.  Preoperative pelvic MRI and 2-[18F]FDG PET/CT for lymph node staging and prognostication in endometrial cancer-time to revisit current imaging guidelines?

Authors:  Kristine E Fasmer; Ankush Gulati; Julie A Dybvik; Kari S Wagner-Larsen; Njål Lura; Øyvind Salvesen; David Forsse; Jone Trovik; Johanna M A Pijnenborg; Camilla Krakstad; Ingfrid S Haldorsen
Journal:  Eur Radiol       Date:  2022-06-28       Impact factor: 5.315

Review 4.  Implications of the new FIGO staging and the role of imaging in cervical cancer.

Authors:  Aki Kido; Yuji Nakamoto
Journal:  Br J Radiol       Date:  2021-05-14       Impact factor: 3.629

5.  Asian Society of Gynecologic Oncology International Workshop 2018.

Authors:  Tae Wook Kong; Hee Sug Ryu; Seung Cheol Kim; Takayuki Enomoto; Jin Li; Kenneth H Kim; Seung Hyuk Shim; Peng Hui Wang; Suwanit Therasakvichya; Yusuke Kobayashi; Maria Lee; Tingyan Shi; Shin Wha Lee; Mikio Mikami; Satoru Nagase; Myong Cheol Lim; Jianliu Wang; Sarikapan Wilailak; Sang Wun Kim; Sook Hee Hong; David Sp Tan; Masaki Mandai; Suk Joon Chang; Ruby Yun Ju Huang; Kimio Ushijima; Jung Yun Lee; Xiaojun Chen; Kazunori Ochiai; Taek Sang Lee; Bingyi Yang; Farhana Kalam; Qiaoying Lv; Mohd Faizal Ahmad; Muhammad Rizki Yaznil; Kanika Batra Modi; Manatsawee Manopunya; Dae Hoon Jeong; Arb Aroon Lertkhachonsuk; Hyun Hoon Chung; Hidemichi Watari; Seob Jeon
Journal:  J Gynecol Oncol       Date:  2019-01-14       Impact factor: 4.401

Review 6.  Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri.

Authors:  Jonathan S Berek; Koji Matsuo; Brendan H Grubbs; David K Gaffney; Susanna I Lee; Aoife Kilcoyne; Gi Jeong Cheon; Chong Woo Yoo; Lu Li; Yifeng Shao; Tianhui Chen; Miseon Kim; Mikio Mikami
Journal:  J Gynecol Oncol       Date:  2018-12-28       Impact factor: 4.401

7.  Comparison of integrated PET/MRI with PET/CT in evaluation of endometrial cancer: a retrospective analysis of 81 cases.

Authors:  Li-Hua Bian; Min Wang; Jing Gong; Hong-Hong Liu; Nan Wang; Na Wen; Wen-Sheng Fan; Bai-Xuan Xu; Ming-Yang Wang; Ming-Xia Ye; Yuan-Guang Meng
Journal:  PeerJ       Date:  2019-07-15       Impact factor: 2.984

Review 8.  What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

Authors:  Ingfrid S Haldorsen; Njål Lura; Jan Blaakær; Daniela Fischerova; Henrica M J Werner
Journal:  Curr Oncol Rep       Date:  2019-07-29       Impact factor: 5.075

Review 9.  Value of PET imaging for radiation therapy.

Authors:  Constantin Lapa; Ursula Nestle; Nathalie L Albert; Christian Baues; Ambros Beer; Andreas Buck; Volker Budach; Rebecca Bütof; Stephanie E Combs; Thorsten Derlin; Matthias Eiber; Wolfgang P Fendler; Christian Furth; Cihan Gani; Eleni Gkika; Anca-L Grosu; Christoph Henkenberens; Harun Ilhan; Steffen Löck; Simone Marnitz-Schulze; Matthias Miederer; Michael Mix; Nils H Nicolay; Maximilian Niyazi; Christoph Pöttgen; Claus M Rödel; Imke Schatka; Sarah M Schwarzenboeck; Andrei S Todica; Wolfgang Weber; Simone Wegen; Thomas Wiegel; Constantinos Zamboglou; Daniel Zips; Klaus Zöphel; Sebastian Zschaeck; Daniela Thorwarth; Esther G C Troost
Journal:  Strahlenther Onkol       Date:  2021-07-14       Impact factor: 3.621

Review 10.  Quantitative imaging of uterine cancers with diffusion-weighted MRI and 18-fluorodeoxyglucose PET/CT.

Authors:  Madeleine Sertic; Aoife Kilcoyne; Onofrio Antonio Catalano; Susanna I Lee
Journal:  Abdom Radiol (NY)       Date:  2021-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.